International Journal of Vascular Medicine / 2010 / Article / Tab 1 / Review Article
Mesoglycan: Clinical Evidences for Use in Vascular Diseases Table 1 Mesoglycan in ischemic stroke. Clinical studies.
Author Study design Pathology Patients (
) Doses/route Results Orefice [12 ] Prospective Stroke (1–3 mo before) 30 Mesoglycan 50 mg twice daily orally for 3 months Mesoglycan: safe and effective in reducing FBR without interfering with other coagulative parameters Orefice [11 ] Randomized Controlled Stroke (2-3 mo before) 46 Mesoglycan 50 mg twice daily orally versus Ticlopidine 250 mg twice daily, for 2 months Mesoglycan and ticlopidine: both safe and effective in reducing FBR without interfering with other coagulative parameters Vecchio [13 ] Prospective Stroke (within 2 mo) 20 Mesoglycan 30 mg twice daily intramuscular, for 15 days Mesoglycan: significant reduction in FBR, cholesterol, triglycerides, improved erythrocyte filterability without interfering with other coagulative parameters Mansi [14 ] Prospective TIA or stroke (within 3 mo) 30 Mesoglycan 50 mg twice daily orally Mesoglycan decreases neurologic deficits Forconi [15 ] Multicenter clinical trial History of stroke, TIA, RIND or minor stroke 1,398 Mesoglycan 30 mg twice daily i.m., then 100 mg daily orally, versus ASA 300 mg daily No differences. ASA: higher incidence of side effects